EC Pulmonology and Respiratory Medicine

After centuries of empirical experience in treating acute nonspecific inflammation in the lung (ANSIL), or, to use the more common term, acute pneumonia (AP), significant progress in the treatment of inflammatory processes was achieved by the middle of the last century. Rapid advances in microbiology and the initial results of antimicrobial therapy, especially after the discovery of antibiotics, were perceived by specialists as establishing the cause of the disease and a decisive victory in the treatment of such patients. However, this narrow understanding of the essence of the problem and the subsequent adherence to this ideology, which persisted despite mounting conflicting data without significant correction, led to a cascade of subsequent incorrect conclusions and misconceptions.

1. Podolsky SH. “The changing fate of pneumonia as a public health concern in 20^th-century America and beyond”. American Journal of Public Health 12 (2005): 2144-2154.
2. Metlay JP., et al. “Diagnosis and treatment of adults with community-acquired pneumonia. An official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine 7 (2019): e45-e67.
3. Bender RG., et al. “Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021”. Lancet Infectious Diseases 9 (2024): 974-1002.
4. Cilloniz C., et al. “World pneumonia day 2024: Fighting pneumonia and antimicrobial resistance”. American Journal of Respiratory and Critical Care Medicine 11 (2024): 1283-1285.
5. Serwecińska Liliana. "Antimicrobials and antibiotic-resistant bacteria: a risk to the environment and to public health". Water 12 (2020): 3313.
6. World Health Organization. “Antimicrobial resistance” (2023).
7. Madhavi Thara. “Antibiotic Stewardship”. Medicon Medical Sciences3 (2024): 01-02.
8. Churpek MM., et al. “Hospital-level variation in death for critically ill patients with COVID-19”. American Journal of Respiratory and Critical Care Medicine 204 (2021): 403-411.
9. Cilloniz C., et al. “World pneumonia day 2024: Fighting pneumonia and antimicrobial resistance”. American Journal of Respiratory and Critical Care Medicine 11 (2024): 1283-1285.
10. Gross CP., et al. “Artificial intelligence and clinical care: JAMA internal medicine call for papers”. JAMA Internal Medicine 12 (2025): 1418-1420.
11. Ziad Obermeyer. “Bedside to Bench - AI and the new science of medicine”. New England Journal of Medicine 23 (2025): 2287-2289.
12. Abraham EP and Chain E. “An enzyme from bacteria able to destroy penicillin. 1940”. Review of Infectious Diseases 4 (1988): 677-678.
13. Rammelkamp T. “Resistance of Staphylococcus aureus to the action of penicillin”. Experimental Biology and Medicine 51 (1942): 386-389.
14. Antimicrobial resistance (2021).
15. Sakamoto Y., et al. “In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: a matched-pair cohort study”. BMC Pulmonary Medicine 1 (2021): 345.
16. Ding H., et al. “Incidence of drug-resistant pathogens in community-acquired pneumonia at a safety net hospital”. Microbiology Spectrum 8 (2024): e00792-24.
17. Gohil SK., et al. “Initial antibiotic selection strategy and subsequent antibiotic use-insights from the INSPIRE trials”. Journal of the American Medical Association 12 (2025): 1107-1109.
18. Aubry-Damon H., et al. “Antimicrobial resistance in commensal flora of pig farmers”. Emerging Infectious Diseases 5 (2004): 873-879.
19. Albrich WC and Harbarth S. “Health-care workers: Source, vector, or victim of MRSA?” Lancet Infectious Diseases 5 (2008): 289-301.
20. Graveland H., et al. “Methicillin resistant Staphylococcus aureus ST398 in veal calf farming: human MRSA carriage related with animal antimicrobial usage and farm hygiene”. PLoS ONE 5 (2010): e10990.
21. C Heneghan., et al. “Differentiating viral from bacterial pneumonia”. The Centre for Evidence-Based Medicine. Evidence Service to support the COVID-19 response. University of Oxford (2020).
22. Kamat IS., et al. “Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis”. Clinical Infectious Diseases 3 (2020): 538-542.
23. Lhommet C., et al. “Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?” BMC Pulmonary Medicine 1 (2020): 62.
24. Pan D., et al. “Management of pneumonia in the critically ill”. Minerva Medica 5 (2023): 667-682.
25. Zhang JH., et al. “Optimizing patient outcomes in severe pneumonia: the role of multiplex PCR in the treatment of critically ill patients”. Front Med (Lausanne) 11 (2024): 1391641.
26. Palomeque A., et al. “A review of the value of point-of-care testing for community-acquired pneumonia”. Expert Review of Molecular Diagnostics8 (2024): 729-742.
27. Shan H and Chen R. “Life support use and outcomes among patients admitted to intensive care units”. JAMA (2025).
28. Ling L., et al. “Bacterial multiplex polymerase chain reaction tests for the diagnosis and management of pneumonia: ready for prime time?” Thorax 11 (2025): 862-872.
29. Nuala Meyer. “Dysregulated host immune response is the driver of disease progression and severe patient outcomes”. Respiratory AMJ 1 (2023): 26-35.
30. Pratik Sinha. “Severe viral lower respiratory tract infections pose a significant burden on patients and healthcare systems”. Respiratory AMJ 1 (2023): 26-35.
31. I Klepikov. “Myths, legends and real facts about acute lung inflammation”. Cambridge Scholars Publishing (2024): 338.
32. Thillai M., et al. “Functional respiratory imaging identifies redistribution of pulmonary blood flow in patients with COVID-19”. Thorax 2 (2021): 182-184.
33. W Dierckx., et al. “CT-derived measurements of pulmonary blood volume in small vessels and the need for supplemental oxygen in COVID-19 patients”. Journal of Applied Physiology6 (2022): 1295-1299.
34. Rhee C., et al. “Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals”. JAMA Network Open 2 (2019): e187571.
35. “Sepsis” (2024).
36. Meyer Nuala J and Prescott Hallie C. "Sepsis and septic shock". New England Journal of Medicine22 (2024): 2133-2146.
37. Martin-Loeches I., et al. “ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia”. Intensive Care Medicine 6 (2023): 615-632.
38. Aurélien Dinh., et al. “Update of guidelines for management of Community Acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF): Endorsed by the French intensive care society (SRLF), the French microbiology society (SFM), the French radiology society (SFR) and the French emergency society (SFMU)”. Respiratory Medicine and Research 87 (2025): 101161.